Drug Database
Back to search

Belgium· BE-AMP-SAM664155-00

Rybrevant 1600 mg

A amivantamab product containing amivantamab, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 15 of our 19 countries.

ATC L01FX18

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedRybrevant 1600 mgATCL01FX18REGISTER NO.BE-AMP-SAM664155-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about amivantamabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Amivantamab is registered in 15 of 19 countries.

Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search amivantamab products by name

Amivantamab · ATC L01FX18

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of amivantamab costs, country by country.

Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Amivantamab · price per daily dose (75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$335.64
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Amivantamab
Manufacturer
Janssen-Cilag International
Country
Belgium (BE)
ATC code
L01FX18
ATC class
Amivantamab
Defined daily dose
75 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    4908943
  • be_apb
    7749377

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Amivantamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amivantamab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rybrevant
  • Liechtenstein · Rybrevant
  • Norway · Rybrevant

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e3b6bebb-8e30-4875-a16a-de5e7113a177
GET /v1/drugs/e3b6bebb-8e30-4875-a16a-de5e7113a177?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Rybrevant 1600 mg",
  "name_fr": "Rybrevant 1600 mg",
  "name_nl": "Rybrevant 1600 mg",
  "amp_code": "SAM664155-00",
  "strengths": [
    "160.0000",
    "160.0000",
    "0.6000"
  ],
  "pack_count": 1,
  "substances": [
    "Amivantamab",
    "Disodium Ethylenediaminetetraacetic Acid (EDTA) Dihydrate",
    "Sodium Acetate Trihydrate",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Amivantamab",
  "authorisation_numbers": [
    "EU/1/21/1594/002"
  ]
}
API referenceMCP serverPlans

See everything about amivantamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console